At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women
In Brief
A clinical study evaluating Fluoxetine, Zolpidem, and 1 other intervention for Healthy. Completed, enrolled 8 participants across 1 site.
Detailed Summary
The goal of this series of challenge studies is to examine the impact of menstrual cycle phase on cortical GABA response to administration of agents with either direct (benzodiazepines) or indirect (progesterone, fluoxetine) GABA modulating properties. While the impact of these agents on cortical GABA levels in women with premenstrual dysphoric disorder (PMDD) is of interest, this study is designed primarily for those women without a psychiatric illness.
Study Details
Timeline
Interventions
Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.